jac-1 Antibody

What is JAK1 and why is it important in research?

JAK1 (Janus kinase 1) is a member of the protein-tyrosine kinase (PTK) family characterized by a second phosphotransferase-related domain immediately N-terminal to the PTK domain. It plays an essential role in cellular signaling pathways involved in immune response, cell growth, and oncogenesis . JAK1 is particularly significant in research because it serves as a critical mediator in multiple cytokine signaling pathways, making it relevant to studies of inflammation, cancer biology, and immunological disorders.

What applications can JAK1 antibodies be used for in research?

JAK1 antibodies demonstrate utility across multiple experimental platforms. Based on validation data, JAK1 antibodies can be employed in Western blotting (1:1000-1:6000 dilution), immunohistochemistry (1:100-1:400 dilution), immunofluorescence, immunoprecipitation, and ELISA . These applications enable researchers to detect JAK1 protein expression, localization, and interaction with other proteins across various experimental contexts.

What sample types are compatible with JAK1 antibodies?

JAK1 antibodies show reactivity with samples from multiple species including human, rat, and mouse tissues and cell lines . Specifically, positive Western blot detection has been reported in K-562 cells, Jurkat cells, rat spleen tissue, PC-12 cells, NIH/3T3 cells, RAW 264.7 cells, Ramos cells, and Daudi cells . For immunohistochemistry, validated results have been obtained with human breast cancer tissue and human cervical cancer tissue .

How should I validate JAK1 antibody specificity for my experimental system?

Validating antibody specificity is crucial for reliable results. A comprehensive validation approach should include:

• Positive and negative controls: Use cell lines or tissues known to express JAK1 (e.g., K-562, Jurkat cells) as positive controls and JAK1 knockout or knockdown samples as negative controls .

• Multiple detection methods: Confirm JAK1 detection using at least two independent methods (e.g., Western blot and immunohistochemistry).

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to confirm signal elimination.

• Cross-reactivity testing: Ensure the antibody doesn't detect related proteins like JAK2, JAK3, or TYK2, particularly in multiplex assays.

The literature contains references to JAK1 antibody validation in knockdown/knockout studies, with at least 2 publications supporting its specificity in such experimental contexts .

What are the optimal conditions for JAK1 antibody use in immunohistochemistry?

For optimal immunohistochemical detection of JAK1:

• Antigen retrieval: Use TE buffer at pH 9.0 as the primary recommendation. Alternatively, citrate buffer at pH 6.0 may be used .

• Antibody dilution: Start with a dilution range of 1:100-1:400 and optimize based on your specific tissue type .

• Incubation conditions: Typically, overnight incubation at 4°C produces optimal results, though specific protocols may vary.

• Detection system: Use a detection system appropriate for the mouse IgG2b isotype of this antibody .

• Counterstaining: Hematoxylin counterstaining can provide cellular context without interfering with DAB-based signal detection.

How can I troubleshoot weak or absent signal when using JAK1 antibody in Western blotting?

Several methodological approaches can address weak JAK1 detection:

• Sample preparation optimization:

  • Ensure complete cell lysis with appropriate buffers containing phosphatase and protease inhibitors

  • Verify protein concentration and loading consistency

  • Consider enriching for membrane fractions where JAK1 is predominantly located

• Transfer optimization:

  • For this 133 kDa protein , extend transfer time or reduce gel percentage to facilitate complete transfer

  • Consider using PVDF membrane instead of nitrocellulose for better protein retention

• Antibody conditions:

  • Increase primary antibody concentration (up to 1:1000 dilution)

  • Extend primary antibody incubation time to overnight at 4°C

  • Use fresh antibody and verify it has been stored properly in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Detection optimization:

  • Use enhanced chemiluminescence reagents with longer exposure times

  • Consider signal amplification systems for low abundance samples

How do I resolve non-specific binding or high background in JAK1 immunostaining?

To improve signal-to-noise ratio in JAK1 immunostaining:

• Blocking optimization:

  • Extend blocking time to at least 1-2 hours

  • Test alternative blocking agents (BSA, normal serum, commercial blockers)

  • Include 0.1-0.3% Triton X-100 in blocking solution for improved penetration

• Antibody dilution:

  • Further dilute primary antibody (start with 1:400)

  • Reduce secondary antibody concentration

  • Extend washing steps between antibody incubations

• Sample-specific considerations:

  • For tissues with high endogenous peroxidase activity, use hydrogen peroxide pre-treatment

  • For tissues with high background, consider using M.O.M. kit for mouse antibodies on mouse tissues

• Alternative detection:

  • Switch to fluorescent detection if DAB produces high background

  • Consider tyramide signal amplification for specific enhancement

How can I use JAK1 antibodies to study JAK1 phosphorylation status?

Studying JAK1 phosphorylation requires specific methodological considerations:

• Phospho-specific antibodies: While the general JAK1 antibody (66466-1-Ig) detects total JAK1 protein , phospho-specific antibodies are required to detect activation status at specific residues (e.g., Y1022/Y1023).

• Sample preparation:

  • Rapidly harvest cells to preserve phosphorylation status

  • Use phosphatase inhibitor cocktails in all buffers

  • Consider stimulating cells with appropriate cytokines (e.g., IL-6, IFN-γ) to enhance phosphorylation

• Sequential immunoblotting:

  • First detect phospho-JAK1 on membranes

  • Strip and reprobe with total JAK1 antibody

  • Calculate phospho/total JAK1 ratio for quantitative assessment

• Complementary approaches:

  • Utilize phospho-flow cytometry for single-cell resolution

  • Consider proximity ligation assay to detect JAK1 interaction with STAT proteins as functional readout of JAK1 activation

What strategies can optimize JAK1 antibody-based immunoprecipitation?

For effective JAK1 immunoprecipitation:

• Antibody selection: Ensure the antibody recognizes the native conformation of JAK1. The literature contains at least one publication validating the use of this antibody in immunoprecipitation applications .

• Lysis conditions:

  • Use mild, non-denaturing lysis buffers (e.g., NP-40 or CHAPS-based)

  • Include protease and phosphatase inhibitors

  • Perform lysis at 4°C with minimal mechanical disruption

• Pre-clearing:

  • Pre-clear lysates with protein A/G beads

  • Remove non-specific binding proteins with isotype control antibodies

• Optimization strategy:

  • Test different antibody-to-lysate ratios

  • Consider cross-linking antibody to beads to prevent antibody contamination in eluates

  • Compare different elution conditions (pH, ionic strength, competitive elution)

• Verification:

  • Confirm JAK1 presence in immunoprecipitates by Western blot

  • Assess co-precipitating proteins (e.g., cytokine receptors, STAT proteins)

How can JAK1 antibodies be incorporated into multiplex immunoassays?

Multiplex detection involving JAK1 requires careful planning:

• Antibody compatibility:

  • Ensure JAK1 antibody (mouse IgG2b isotype) is compatible with other primary antibodies in species and isotype

  • Test for cross-reactivity with other JAK family members

• Panel design:

  • Include complementary markers in JAK-STAT pathway (e.g., STAT1, STAT3)

  • Consider receptor components and downstream targets for comprehensive pathway analysis

• Signal separation:

  • For fluorescent multiplex, select fluorophores with minimal spectral overlap

  • For chromogenic multiplexing, use sequential detection with complete stripping between rounds

• Validation approach:

  • Test each antibody individually before combining

  • Use single-stained controls for spectral compensation

  • Include biological controls with known JAK1 expression patterns

What considerations are important when using JAK1 antibodies across different species?

The JAK1 antibody has demonstrated reactivity with human, rat, and mouse samples , but cross-species applications require special attention:

• Sequence homology assessment:

  • Verify the conservation of the epitope recognized by this antibody across species

  • The immunogen used for this antibody was a JAK1 fusion protein (Ag17940)

• Species-specific validation:

  • Test antibody on positive and negative controls from each species

  • Adjust antibody concentration for species-specific optimization

  • Consider species-specific secondary antibodies to reduce background

• Application-specific considerations:

  • For IHC in non-human tissues, optimize antigen retrieval conditions

  • For WB, verify the expected molecular weight across species (133 kDa in human)

  • For IF, assess background autofluorescence in tissues from different species

• Alternative approaches:

  • For poorly-conserved epitopes, consider using species-specific antibodies

  • Verify findings with orthogonal methods (e.g., mRNA expression)

How can JAK1 antibodies contribute to cancer research beyond detection?

Beyond basic detection, JAK1 antibodies enable several advanced cancer research applications:

• Therapeutic response monitoring:

  • Assess JAK1 expression/phosphorylation changes in response to JAK inhibitors

  • Evaluate changes in JAK1 status in resistant vs. sensitive tumors

  • Monitor JAK1 in patient samples during clinical trials

• Biomarker development:

  • Correlate JAK1 expression patterns with clinical outcomes

  • Develop JAK1-based diagnostic or prognostic indicators

  • Standardize JAK1 detection for potential clinical application

• Mechanistic studies:

  • Use JAK1 antibodies in ChIP-seq to identify JAK1-associated chromatin regions

  • Employ proximity labeling to identify novel JAK1 interaction partners

  • Study non-canonical JAK1 functions beyond STAT activation

The JAK1 antibody has been validated in both breast cancer and cervical cancer tissues, supporting its utility in oncology research .

What methodological approaches can assess JAK1 inhibitor efficacy using antibody-based assays?

JAK1 inhibitors are increasingly important in research and therapy, and antibody-based assessment offers several advantages:

• Target engagement assays:

  • Use JAK1 antibodies in cellular thermal shift assays (CETSA) to confirm inhibitor binding

  • Employ JAK1 antibodies in drug affinity responsive target stability (DARTS) assays

• Functional readouts:

  • Measure phospho-JAK1 reduction after inhibitor treatment

  • Assess downstream STAT phosphorylation changes

  • Quantify nuclear translocation of STAT proteins

• Resistance mechanisms:

  • Monitor JAK1 expression changes during acquired resistance

  • Detect JAK1 mutations that confer inhibitor resistance

  • Identify compensatory pathway activation

• In vivo applications:

  • Use JAK1 antibodies for pharmacodynamic biomarker development

  • Perform IHC on treated xenograft tissues to confirm target inhibition

  • Correlate JAK1 status with treatment outcomes

What are the current limitations of JAK1 antibodies and how might they be addressed?

Despite their utility, current JAK1 antibodies face several limitations:

• Specificity challenges:

  • Cross-reactivity with other JAK family members remains a concern

  • Development of monoclonal antibodies with enhanced epitope specificity

  • Implementation of extensive validation using CRISPR knockout controls

• Dynamic range limitations:

  • Current antibodies may not accurately quantify the full range of JAK1 expression

  • Development of calibrated standards for quantitative immunoassays

  • Integration with mass spectrometry for absolute quantification

• Phosphorylation site specificity:

  • Need for antibodies that reliably distinguish between different phosphorylation patterns

  • Development of conformation-specific antibodies that detect active vs. inactive JAK1

  • Creation of biosensor antibodies that report JAK1 activation in real-time

• Technical improvements:

  • Engineering recombinant antibody fragments for improved tissue penetration

  • Developing pH-resistant antibodies for endosomal tracking applications

  • Creating bifunctional antibodies for simultaneous detection of JAK1 and binding partners